CNY:PA:PA-HSBC MSCI China UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.023

Change

-0.08 (-1.57)%

Market Cap

USD 0.61B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-16 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
WRD:PA HSBC ETFs Public Limited Compa..

+0.01 (+0.04%)

USD 9.26B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-0.25 (-0.05%)

USD 8.86B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+0.45 (+0.19%)

USD 7.39B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-0.25 (-0.06%)

USD 6.76B
HHH:PA HSBC ETFs Public Limited Compa..

-0.03 (-0.06%)

USD 6.63B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.35 (+0.11%)

USD 6.20B
LCWD:PA Multi Units Luxembourg - Lyxor..

+0.01 (+0.03%)

USD 4.86B
WSRI:PA Amundi MSCI World SRI Climate ..

+0.31 (+0.34%)

USD 4.32B
500U:PA Amundi Index Solutions - Amund..

+0.33 (+0.33%)

USD 4.28B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

-0.14 (-0.11%)

USD 3.71B

ETFs Containing CNY:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.57% 24% F 39% F
Dividend Return N/A 9% A- 14% F
Total Return N/A 41% F 53% F
Trailing 12 Months  
Capital Gain -17.66% 7% C- 27% F
Dividend Return N/A 51% F 30% F
Total Return N/A 19% F 21% F
Trailing 5 Years  
Capital Gain -34.51% 7% C- 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.51% 7% C- 20% F
Average Annual (5 Year Horizon)  
Capital Gain 1.72% 37% F 43% F
Dividend Return N/A 48% F 25% F
Total Return N/A 22% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) N/A 58% F 23% F
Risk Adjusted Return N/A 1% F 61% D-
Market Capitalization 0.61B 75% C 74% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.